MedPath

Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia

Phase 3
Completed
Conditions
Community-acquired Pneumonia
Bacterial Pneumonia
Registration Number
NCT04779242
Lead Sponsor
Paratek Pharmaceuticals Inc
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
670
Inclusion Criteria

Inclusion Criteria:<br><br> - Male or female subjects, age 18 or older who have signed the informed consent form<br><br> - Must have a qualifying community-acquired bacterial pneumonia<br><br> - Subjects must not be pregnant or nursing at the time of enrollment<br><br> - Must agree to a reliable method of birth control during the study and for 30 days<br> following the last dose of study drug<br><br>Exclusion Criteria:<br><br> - Known or suspected hospital-acquired pneumonia<br><br> - Confirmed or suspected SARS-CoV-2 infection<br><br> - Evidence of significant immunological disease<br><br> - Has a life expectancy of less than or equal to 3 months or any concomitant condition<br> that is likely to interfere with evaluation of the response of the infection under<br> study, determination of AEs, or completion of the expected course of treatment<br><br> - Has a history of contraindications, hypersensitivity, or allergic reaction to any<br> tetracycline or fluoroquinolone antibiotic<br><br> - Has received an investigational drug within the past 30 days

Exclusion Criteria

Not provided

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Number of participants with early clinical response in the Intent-to-Treat (ITT) Population at the Early Clinical Response (ECR) visit
Secondary Outcome Measures
NameTimeMethod
Number of participants with the indicated investigator assessment of clinical response in the Intent-to-Treat (ITT) Population at the Post Therapy Evaluation (PTE) Visit;Number of participants with the indicated investigator assessment of clinical response in the Clinically Evaluable-Post Therapy Evaluation (CE-PTE) Population at the Post-Therapy Evaluation (PTE) Visit
© Copyright 2025. All Rights Reserved by MedPath